See more : Blue Dart Express Limited (BLUEDART.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Progyny, Inc. (PGNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Progyny, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Yuh Shan (7715.TWO) Income Statement Analysis – Financial Results
- Prinsiri Public Company Limited (PRIN.BK) Income Statement Analysis – Financial Results
- Evergreen International Storage & Transport Corporation (2607.TW) Income Statement Analysis – Financial Results
- TIAAN CONSUMER LIMITED (TIAANC.BO) Income Statement Analysis – Financial Results
- Studio Santa Claus Entertainment Co., Ltd. (204630.KQ) Income Statement Analysis – Financial Results
Progyny, Inc. (PGNY)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.progyny.com
About Progyny, Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 786.91M | 500.62M | 344.86M | 229.68M | 105.40M | 48.58M |
| Cost of Revenue | 849.80M | 619.59M | 388.49M | 274.80M | 184.18M | 85.97M | 41.18M |
| Gross Profit | 238.80M | 167.33M | 112.14M | 70.06M | 45.51M | 19.43M | 7.40M |
| Gross Profit Ratio | 21.94% | 21.26% | 22.40% | 20.32% | 19.81% | 18.44% | 15.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 117.13M | 98.33M | 59.62M | 46.71M | 23.93M | 15.60M | 14.15M |
| Selling & Marketing | 59.49M | 45.66M | 20.18M | 15.01M | 11.90M | 7.29M | 4.26M |
| SG&A | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Other Expenses | 0.00 | 286.00K | -366.00K | 210.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Cost & Expenses | 1.03B | 763.57M | 468.28M | 336.51M | 220.01M | 108.85M | 59.59M |
| Interest Income | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 2.28M | 1.60M | 1.30M | 1.91M | 2.13M | 1.88M | 1.56M |
| EBITDA | 64.47M | 24.94M | 33.64M | 10.25M | 11.81M | -1.57M | -9.45M |
| EBITDA Ratio | 5.92% | 3.17% | 6.72% | 2.97% | 13.06% | 1.30% | -17.97% |
| Operating Income | 62.18M | 23.34M | 32.34M | 8.35M | 27.85M | -3.45M | -11.01M |
| Operating Income Ratio | 5.71% | 2.97% | 6.46% | 2.42% | 12.13% | -3.28% | -22.65% |
| Total Other Income/Expenses | 8.51M | 1.10M | 95.00K | 331.00K | -18.23M | -3.44M | -1.45M |
| Income Before Tax | 70.69M | 24.44M | 32.44M | 8.68M | -8.56M | -6.89M | -12.46M |
| Income Before Tax Ratio | 6.49% | 3.11% | 6.48% | 2.52% | -3.73% | -6.54% | -25.64% |
| Income Tax Expense | 8.65M | -5.92M | -33.33M | -37.78M | 12.00K | -1.78M | -3.00K |
| Net Income | 62.04M | 30.36M | 65.77M | 46.46M | -8.57M | 661.00K | -12.45M |
| Net Income Ratio | 5.70% | 3.86% | 13.14% | 13.47% | -3.73% | 0.63% | -25.63% |
| EPS | 0.65 | 0.33 | 0.74 | 0.54 | -0.10 | 0.01 | -0.18 |
| EPS Diluted | 0.62 | 0.30 | 0.66 | 0.47 | -0.10 | 0.01 | -0.15 |
| Weighted Avg Shares Out | 95.02M | 92.20M | 89.11M | 85.72M | 83.57M | 81.56M | 70.59M |
| Weighted Avg Shares Out (Dil) | 100.67M | 99.96M | 100.36M | 99.06M | 83.57M | 81.56M | 81.56M |
Progyny: No Change To Long-Term Outlook
PGNY experienced a revenue miss in 1Q24 due to weak utilization. Historical data shows that IVF demand has been resilient, with strong rebounds following economic downturns. Leading indicators suggest that utilization rates are already improving, and demand remains solid, indicating...
Progyny's board approves another $100 million stock buyback
The board of Progyny PGNY, -2.62% has approved a $100 million share-repurchase authorization, its second this year.
Progyny, Inc. Announces Additional Share Repurchase Program
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, announced today that its Board of Directors has approved a share repurchase program to repurchase up to $100...
Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Progyny's executives will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference...
Progyny's stock plunges as demand for IVF treatments drops after Alabama ruling
Shares of Progyny Inc. were headed for a record selloff Friday after the fertility-services company said the Supreme Court of Alabama's February ruling regarding in vitro fertilization seemed to scare off some potential customers.
Why Is Progyny (PGNY) Stock Down 27% Today?
Progyny (NASDAQ: PGNY ) stock is falling hard on Friday after the fertility and family-building benefits solutions company announced earnings results for its first quarter of 2024. The bad news for PGNY investors starts with its revenue of $278.08 million during the...
Progyny, Inc. (PGNY) Q1 2024 Earnings Call Transcript
Progyny, Inc. (NASDAQ:PGNY ) Q1 2024 Earnings Conference Call May 9, 2024 4:45 PM ET Company Participants James Hart – Investor Relations Pete Anevski – Chief Executive Officer Mark Livingston – Chief Financial Officer Michael Sturmer – President Conference Call...
Progyny, Inc. Announces First Quarter 2024 Results
Early Sales Activity and New Partnerships Provide Strong Start to Selling Season, Affirming Continued Demand for Fertility and Family Building Solutions Early Sales Activity and New Partnerships Provide Strong Start to Selling Season, Affirming Continued Demand for Fertility and Family...
Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended March 31, 2024 after the close of the...
Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care
The organizations will host an event with Canada's leading providers, employers, and fertility advocates to show support for the millions in need of family building care The organizations will host an event with Canada's leading providers, employers, and fertility advocates...
Source: https://incomestatements.info
Category: Stock Reports